Biohm Technologies is a Cleveland-based microbiome innovation company that studies the gut as a whole - bacteria and fungi together - rather than bacteria alone. Built on 40+ years of fungal research by Dr. Mahmoud Ghannoum, the scientist who named the mycobiome, Biohm develops data-driven biotic ingredients and gut-health testing solutions. Its flagship ingredient Mycohsa is the first probiotic blend clinically shown to break down digestive biofilms, and its Symbiont discovery platform mines a large bacterial-fungal dataset to design targeted microbiome products. After a B2B pivot in 2024, the company now sells ingredients and microbiome science to nutraceutical and food brands.
Sam Schatz is the CEO and co-founder of Biohm Technologies, a Cleveland-based microbiome company betting that the future of gut health lives in fungi, not just bacteria. After spending a decade as AeroFarms' first employee scaling vertical farming from a startup into a global leader, he pivoted to the gut, turning a direct-to-consumer wellness brand into a B2B ingredients and data company built on a proprietary dataset of bacterial and fungal gut populations. He pairs data science with biology, raised a $4.52M Series B in 2025, and shipped Mycohsa, a probiotic blend clinically shown to break down digestive biofilms. Off the clock he is an Adirondack 46er and open-water swimmer.